First-line ribociclib plus letrozole in patients with de novo HR+, HER2-advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreFirst-line ribociclib plus letrozole in patients with de novo HR+, HER2-advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial
Type de publicationJournal Article
Year of Publication2017
AuteursO'Shaughnessy J., Petrakova K., Sonke G.S, Andre F., Conte P., Arteaga C.L, Cameron D.A, Hart L.L, Villanueva C., Jakobsen E.H, Lindquist D., Souami F., Li X., Germa C., Hirawatand S., Hortobagyi G.N
JournalCANCER RESEARCH
Volume77
Date PublishedFEB
Type of ArticleMeeting Abstract
ISSN0008-5472
Mots-clésAdvanced breast cancer, CDK4/6 inhibitor, Letrozole, Ribociclib
DOI10.1158/1538-7445.SABCS16-P4-22-05